BioMarin
Trade BioMarin 24 hours a day, five days a week on Robinhood.
Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.About BMRN
BioMarin Pharmaceutical, Inc. engages in the development and commercialization of therapies for people with serious and life-threatening rare diseases and medical conditions. Its pipeline products include Valoctocogene roxaparvovec, Vosoritide, and BMN 307.
BMRN Key Statistics
Stock Snapshot
As of today, BioMarin(BMRN) shares are valued at $60.45. The company's market cap stands at 11.57B, with a P/E ratio of 22.91.
On 2025-12-25, BioMarin(BMRN) stock moved within a range of $59.81 to $61.24. With shares now at $60.45, the stock is trading +1.1% above its intraday low and -1.3% below the session's peak.
Trading volume for BioMarin(BMRN) stock has reached 1.21M, versus its average volume of 4.12M.
Over the past 52 weeks, BioMarin(BMRN) stock has traded between a high of $73.51 and a low of $50.76.
Over the past 52 weeks, BioMarin(BMRN) stock has traded between a high of $73.51 and a low of $50.76.
BMRN News
Truist analyst Joon Lee raised the firm’s price target on BioMarin (BMRN) to $100 from $80 and keeps a Buy rating on the shares. The company’s proposed acquisit...
Claim 50% Off TipRanks Premium and Invest with Confidence Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper...
BofA moved to No Rating from Buy on Amicus Therapeutics (FOLD) after the company announced that it has entered into an agreement to be acquired by BioMarin (BMR...
Analyst ratings
74%
of 27 ratingsMore BMRN News
Claim 50% Off TipRanks Premium and Invest with Confidence Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper...
BioMarin Pharmaceutical (BMRN) has quietly staged a double digit rebound over the past month, even though the longer term chart still shows steep drawdowns that...
BioMarin (BMRN) is up 21.4%, or $11.13 to $63.08. Claim 50% Off TipRanks Premium and Invest with Confidence Unlock hedge-fund level data and powerful investin...
In trading on Friday, shares of BioMarin Pharmaceutical Inc (Symbol: BMRN) crossed above their 200 day moving average of $57.99, changing hands as high as $63.8...
BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) and Amicus Therapeutics, Inc. (NASDAQ:FOLD) shares are trading higher on Friday after the companies penned a merger d...
Yun Zhong, an analyst from Wedbush, maintained the Buy rating on BioMarin Pharmaceutical. The associated price target remains the same with $94.00. Claim 50% Of...
BioMarin Pharmaceutical (BMRN) and Amicus (FOLD) stocks soared on Friday after the two medical companies announced an acquisition agreement. Under the terms of...